Tags

Type your tag names separated by a space and hit enter

Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial.
Front Immunol. 2020; 11:561851.FI

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF

Authors+Show Affiliations

Usmani SS
Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.
Raghava GPS
Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.

MeSH

AnimalsBetacoronavirusCOVID-19COVID-19 VaccinesClinical Trials as TopicCoronavirus InfectionsHumansPandemicsPneumonia, ViralSARS-CoV-2Viral Vaccines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33133071

Citation

Usmani, Salman Sadullah, and Gajendra P S. Raghava. "Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial." Frontiers in Immunology, vol. 11, 2020, p. 561851.
Usmani SS, Raghava GPS. Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. Front Immunol. 2020;11:561851.
Usmani, S. S., & Raghava, G. P. S. (2020). Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. Frontiers in Immunology, 11, 561851. https://doi.org/10.3389/fimmu.2020.561851
Usmani SS, Raghava GPS. Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. Front Immunol. 2020;11:561851. PubMed PMID: 33133071.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial. AU - Usmani,Salman Sadullah, AU - Raghava,Gajendra P S, Y1 - 2020/09/29/ PY - 2020/05/13/received PY - 2020/09/14/accepted PY - 2020/11/2/entrez PY - 2020/11/3/pubmed PY - 2020/11/20/medline KW - COVID-19 KW - SARS-CoV-2 KW - coronavirus KW - immunoinformatic KW - vaccine candidates SP - 561851 EP - 561851 JF - Frontiers in immunology JO - Front Immunol VL - 11 SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/33133071/Potential_Challenges_for_Coronavirus__SARS_CoV_2__Vaccines_Under_Trial_ L2 - https://doi.org/10.3389/fimmu.2020.561851 DB - PRIME DP - Unbound Medicine ER -